Originally formed in 1992 and based in Edinburgh, Archangels is a prominent business angel syndicate which has been at the forefront of early stage investing in Scotland for more than a quarter of a century.

Latest News

Sorting:
  • PhysioMedics Steps in to Tackle Covid19 Lockdown Neck and Back Pain Emergency

    Millions of workers operating from home could be creating a backlog of neck and back pain complaints which the NHS will struggle to cope with. Now physiotherapy experts at PhysioWizard®, the UK’s first clinically validated digital triage service for muscle and joint problems, are so concerned that they have stepped in to offer their online […]

  • Arrayjet Signs Seven Figure US Contract

    Arrayjet has signed a seven-figure deal with CDI Laboratories to further the US firm’s research and development programme. The contract is said to be worth in the region of $1 million (£797,000) and is the second installation of Arrayjet equipment at CDI. The new IRIS Optical system joins the Arrayjet Ultra Marathon II microarray printer […]

  • Archangels Leads Further Investment in Scottish Innovators During Lockdown

    Archangels has led investment of £3.3 million in innovative Scottish companies during the Coronavirus lockdown. Archangels’ Q2 (1st April – 30th June) deals data released today (7th July, 2020) reveals that three of our portfolio companies – Calcivis, BDD and Reactec – have received follow-on funding during the period, with £1.9m of the committed investment […]

  • Reactec Funding Round Supports Development of Social Distancing Tech

    Edinburgh-based Reactec has completed a further £700,000 round of fundraising for the ongoing development of its innovative personal monitoring equipment and reporting technology. This will include its recently launched innovative SAFE-DISTANCE device to enable social distancing among workers. The funding round was led by Archangels, with co-funding from Scottish Investment Bank, the investment arm of […]

  • MGB Biopharma Announces Successful Outcome from Phase II Clinical Study

    Study confirms MGB-BP-3 offers the potential for a new gold standard in treating Clostridium difficile Infection MGB Biopharma, the Glasgow-based biopharmaceutical company developing a novel class of anti-infectives, today announces the successful conclusion of its Phase II clinical study into MGB-BP-3, for the treatment of Clostridium difficile Infection (CDI). The study confirms that the drug […]

Portfolio Companies

See our ‘Impact evaluation of activities report’ by the Hunter Centre for Entrepreneurship at The University of Strathclyde.